Story

RaySearch Stock Plummets 20% After Delayed US Deals Hit Q2 Sales

ENTHMSVIIDZHZH-TWJAKOHI
Jul 16, 20261 min read
RaySearch Stock Plummets 20% After Delayed US Deals Hit Q2 Sales

Summary

Shares of the Swedish medical software firm fell sharply after it reported a decline in preliminary Q2 sales and profit, attributing the weakness to postponed contracts in the United States.

Text size
Background

Shares of RaySearch Laboratories (STO:RAY-B) plunged 20% on Thursday after the Swedish medical technology company released preliminary second-quarter results that fell short of expectations, citing the postponement of several major deals in the United States.

Preliminary Results Disappoint

According to the company's announcement, the weaker-than-anticipated performance was primarily driven by a timing issue with U.S. contracts, which RaySearch stressed have been delayed, not lost. The preliminary figures for the second quarter revealed a significant impact on top and bottom lines:

  • Net sales declined year-over-year, with organic growth at -8%.
  • Operating profit also fell, directly linked to the deferred revenue from the U.S. deals.
Sample IUX Markets – In-articleAd

Contrasting Signals and Outlook

Despite the decline in recognized sales, RaySearch reported that its order intake for the second quarter actually increased compared to the same period last year. This suggests a potentially strong future revenue pipeline once the delayed deals are finalized.

Looking ahead, the company expressed confidence in its performance for the remainder of the year. RaySearch reaffirmed its full-year guidance, maintaining its target for an operating margin of at least 25% for 2026 and anticipating a strong second half.

Read next

More on Stocks
Back to latest news

LATEST